China’s WuXi Biologics - a contract research, development and manufacturing organisation (CRDMO) - has launched a facility in Hangzhou for cGMP manufacturing of microbial-derived products.
List view / Grid view
Global biotechnology company WuXi has demonstrated the success of the CRDMO business model by publishing news of its bumper projects and revenues fuelled by innovative technology platforms in 2021.
New report suggests the cell line development services market will witness a 14.3 percent CAGR between 2021 and 2030.
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.